Beijing Sun-Novo Pharmaceutical Research Co., Ltd. is a contract research organization based in Beijing, China, founded in 2009. It engages in drug research and development in China, operating platforms for external preparations, pediatric drugs, oncology and metabolic diseases, respiratory drug delivery, topical preparations, polypeptide molecular design, genotoxic impurity detection, slow and controlled release preparations, drug synthesis, and quantitative pharmacology. The company also provides services such as SMO, clinical quality management, data management and statistical analysis, project management, clinical trials, TMF document management, quality control, medical writing, medical monitoring, and pharmacovigilance, as well as registration-related services for chemical drugs, biological products, and medical device products. Additionally, it offers biological analysis services through mass spectrometry, immunological analysis, cell biology, and molecular biology platforms, and serves as a Contract Research Organization for professional peptide drug research and development.
Sunshine Nuohe swings to a net loss of 24.4 million yuan in 2026 interim report
Sunshine Nuohe released its 2026 interim report. Total operating revenue was 426 million yuan, down 27.81 percent year on year. Net profit attributable to the parent swung to a loss of 24.4 million yuan, a decrease of 154 million yuan from the same period last year, down 118.79 percent year on year. Net cash flow from operating activities was negative 51.53 million yuan, down 161.25 percent year on year. The company's asset-liability ratio was 46.30 percent, gross margin was 49.19 percent, return on equity was negative 2.03 percent, and diluted earnings per share was negative 0.22 yuan.
Sunshine Novo's H1 revenue hits 426 million yuan as innovative pipeline builds momentum
Sunshine Novo disclosed its 2026 interim report on August 28, reporting revenue of 426 million yuan for the period. The company's strategic transformation is showing results: its self-developed Class 1 innovative drug STC007 for pruritus has completed an out-licensing deal, STC008 for cancer cachexia is advancing in clinical trials, and multiple peptide, small nucleic acid, and CAR-T pipelines have entered the clinical stage. R&D spending rose to 20.54 percent of revenue, with its technology platforms continuing to upgrade. The company remains committed to a dual-engine model of CRO services plus proprietary new drugs, building long-term value through technology commercialization, as its innovation reserves and profit-sharing model gradually lay the foundation for future growth.
Sunshine Nuohe Plans to Acquire Part of Biling Bio's Equity for 10 Million Yuan
Sunshine Nuohe plans to acquire 40,900 yuan of registered capital in Shanghai Biling Biotechnology from Hangzhou Jiaozi Tea for 10 million yuan in cash. After the transaction, the company's stake in Biling Bio will increase from 2.0435 percent to 2.2671 percent. In the most recent year, Biling Bio had total assets of 316 million yuan, net assets of 314 million yuan, revenue of 103,900 yuan, and a loss of about 47.89 million yuan. The company said the deal will support its overall strategic layout in novel nano-conjugated drugs and precision nano-delivery, enhancing competitiveness in the pharmaceutical industry. In the first quarter of 2026, Sunshine Nuohe posted revenue of 197 million yuan and net profit attributable to the parent of 20.63 million yuan.
688621.CG · Capital · Positive Sunshine Nuohe is acquiring a stake in Biling Bio to support its strategic layout in nano-conjugated drugs, enhancing competitiveness.
上海弼领生物技术有限公司 · Capital · Positive Biling Bio receives a cash injection and increased valuation from the acquisition, though it is currently loss-making.
杭州交子茶业有限公司 · Capital · Positive Hangzhou Jiaozi Tea sells part of its stake in Biling Bio for 10 million yuan, realizing a return.
14 positive announcements on the STAR Market: Yandong Microelectronics plans up to 300 million yuan share increase, Kingsoft Office and others report upbeat earnings
The STAR Market today disclosed 14 positive announcements covering share increases, buybacks, earnings growth, and R&D progress. A party acting in concert with Yandong Microelectronics' controlling shareholder, Beijing Electronics Industry Investment Company, plans to increase its stake by 150 million to 300 million yuan within 12 months. Kingsoft Office expects attributable net profit for the first half of 2026 to be between 2.316 billion and 2.719 billion yuan, up 209.98% to 263.89% year-on-year. Sansec Technology expects its half-year loss to narrow by 57.25% year-on-year. Hyperstrong expects attributable net profit for the first half to be between 620 million and 700 million yuan, an increase of 96.30% to 121.63%. In addition, shareholder CEC Capital increased its stake in Dameng Data by 0.01%. Several companies including Orinko Advanced Plastics, Feymer Technology, Chipbond Technology, Canadian Solar, Geling Shentong, Shanghai Yizhong Pharmaceutical, and Actionpower disclosed buyback progress. The controlling shareholder of Zhengyuan Geomatics extended the lock-up period for restricted shares to July 30, 2027. Sunway Pharma's Class 1 innovative drug STC009 injection received clinical trial approval.
Sunshine Nuohe Subsidiary Receives Clinical Trial Approval for STC009 Injection
Sunshine Nuohe's wholly-owned subsidiary, Chengdu Nuohe Shengtai Biotechnology, has received clinical trial approval from the National Medical Products Administration for its Class 1 innovative drug STC009 injection. The drug is intended for the treatment of secondary hyperparathyroidism. It is a calcium-sensing receptor peptide agonist developed using the company's proprietary iCVETide peptide drug discovery platform, and related research findings have been published in the top international journal Journal of Medicinal Chemistry. In the first quarter of 2026, Sunshine Nuohe achieved revenue of 197 million yuan and a net profit attributable to the parent company of 20.63 million yuan.
Sunshine Novo's Controlling Shareholder Li Qian Plans to Transfer 5% Stake via Agreement
Sunshine Novo announced that its controlling shareholder and actual controller Li Qian has signed a share transfer agreement with Ningbo Baojun Asset Management Co., Ltd., representing the Baojun Qiantang No. 6 Growth Private Securities Investment Fund. Li Qian plans to transfer 5.6 million unrestricted tradable shares held directly, representing 5.00% of the company's total share capital, at a price of 41.56 yuan per share, for a total consideration of 233 million yuan. This agreement transfer will not lead to a change in the company's controlling shareholder or actual controller, and does not trigger a mandatory tender offer. The transferee has committed not to reduce its holdings within 12 months after the completion of the share transfer registration.
688621.CG · Capital · Neutral Controlling shareholder transfers 5% stake to a fund; no change in control, but the transaction itself is a capital event with unclear market impact.
Sunshine Nuohe Expects Sharp First-Half Loss; Attributable Net Profit Down Over 111% Year-on-Year
Sunshine Nuohe disclosed its 2026 earnings forecast, projecting attributable net profit for the first half at negative 14.9718 million yuan to negative 29.9436 million yuan, a year-on-year decrease of approximately 144 million yuan to 160 million yuan, representing a decline of 111.53% to 123.06%. Over the same period, attributable net profit after deducting non-recurring items is expected at negative 14.9704 million yuan to negative 29.9408 million yuan, a year-on-year decrease of about 135 million yuan to 150 million yuan, a drop of 112.51% to 125.02%. Based on this, the company's second-quarter attributable net loss is estimated at 35.6028 million yuan to 50.5746 million yuan, a quarter-on-quarter decline of 272.57% to 345.14%, swinging from a first-quarter profit to a substantial loss. The main reason for the turnaround is the absence of large-scale business development revenue booked this year, while the normalization of volume-based procurement policies, intensifying industry competition, and the company's scaling back of low-margin projects have led to reduced orders and revenue in pharmaceutical-related businesses, diminishing profit contributions from traditional operations. Additionally, a significant year-on-year increase in share-based payment amortization expenses from equity incentives further weighed on profitability. Sunshine Nuohe is shifting its growth focus to innovative drug and modified new drug research and development services, a segment that contributed 248 million yuan in revenue in 2025 with a gross margin as high as 96.87%, but project licensing income is highly dependent on deal timing and exhibits significant volatility. The company also plans to raise up to 240 million yuan to invest in a nucleic acid drug discovery and pilot-scale platform, though its small nucleic acid business is still in the early stages of development and is unlikely to generate significant revenue in the short term.
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO ▼Demand
688621.CG · Capital · Negative Company forecasts sharp first-half loss with attributable net profit down over 111% year-on-year due to absence of large-scale business development revenue, reduced orders, and increased share-based payment expenses.
STAR Market Evening Report: Dongxin Shares Expects Niche Memory Prices to Rise in Second Half; JPT to Acquire All Shares of NEOPTICS
Dongxin Shares indicated that the price increase trend for niche memory products continued in the second quarter, and prices are expected to keep rising in the second half of the year. JPT plans to acquire 100% equity in NEOPTICS for 1.12 million Singapore dollars through a wholly owned subsidiary, aiming to strengthen its optical connectivity business. South Korea, together with companies like Samsung and SK, has launched a 312 trillion won investment plan, focusing on the semiconductor and aerospace industries. The National Medical Products Administration plans to include eligible cell and gene therapy drugs in the 30-day review and approval channel for innovative drug clinical trials. Alibaba has completely banned internal use of Claude Code starting July 10 due to the risk of implanted backdoors. This week, the Shanghai Stock Exchange conducted focused monitoring of stocks with abnormal fluctuations such as CSSC Special Gas, Changyingtong, and Yunzhong Technology, as well as funds with high premiums like Caitong Fuxin LOF and Global Chip LOF. Deutsche Bank estimates that Meta's cloud business could generate additional revenue of 9 billion to 30 billion US dollars by 2027. Huaqin Technology signed a framework sales contract for special functional materials for aircraft fuselages worth approximately 278 million yuan. Sun-Novo plans to raise no more than 240 million yuan for nucleic acid drug platform construction. Rushen Robotics and InnoMab completed Pre-A round financing of 100 million yuan and several hundred million yuan, respectively.
Sunshine Novo plans to raise up to 240 million yuan to boost nucleic acid drug R&D
Sunshine Novo has disclosed a simplified procedure private placement plan, aiming to raise total funds of no more than 240 million yuan for the construction of a nucleic acid drug R&D platform and to supplement working capital. The offering will use a simplified procedure, targeting up to 35 professional investment institutions, legal entities, and natural persons. The pricing reference date is the first day of the issuance period, and the issue price will be no lower than 80 percent of the average stock trading price over the 20 trading days before the reference date. Of the raised funds, 190 million yuan will go toward the nucleic acid drug discovery and pilot-scale experimental platform R&D construction project, implemented by subsidiary Arna, to build a nucleic acid drug R&D discovery platform and an injectable pilot-scale experimental R&D platform. The remaining 50 million yuan will be used to supplement working capital. The company's in-house pipeline asset, the ABA001 hypertension nucleic acid injection, received clinical trial acceptance in January 2026. This fundraising will fill gaps in nucleic acid sequence design, CMC pilot-scale work, and clinical translation, establishing an integrated nucleic acid R&D system.
China